Approval · Notice of Compliance 12995 · 2012
NAPROXEN: Notice of Compliance 12995
Issued February 2, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12995
- Date
- February 2, 2012
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic
- Canadian reference product
- ALEVE (Bayer Inc., Consumer Care Division)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAPROXEN | 02362430 | Marketed |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB